Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Puglisi · SciRah

Researcher profile · Semantic Scholar

M. Puglisi

Share profile

M. Puglisi — researcher profile on SciRah

h-index: 16
Works: 45
Citations: 1,122

Most-cited papers

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio, A. Scherpereel, L. Calabrò, J. Aerts +14 more
2017The Lancet Oncology391 citations
Semantic Scholar
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
G. Masi, E. Vasile, F. Loupakis, S. Cupini +16 more
2011Journal of the National Cancer Institute178 citations Open access
Semantic Scholar
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014
B. Basu, E. Dean, M. Puglisi, A. Greystoke +11 more
2015Clinical Cancer Research118 citations Open access
Semantic Scholar
A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.
V. M. García, R. Baird, K. Shah, B. Basu +14 more
2011Journal of Clinical Oncology44 citations
Semantic Scholar
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.
H. Kindler, A. Scherpereel, L. Calabrò, J. Aerts +15 more
201640 citations
Semantic Scholar
First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
U. Banerji, E. Dean, Michael A. Gonzalez, A. Greystoke +9 more
201234 citations
Semantic Scholar
A study of motivations and expectations of patients seen in phase 1 oncology clinics
S. Dolly, E. Kalaitzaki, M. Puglisi, S. Stimpson +11 more
2016Cancer32 citations Open access
Semantic Scholar
ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.
D. Lorusso, N. Colombo, R. Coleman, L. Randall +16 more
202029 citations
Semantic Scholar
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
M. Puglisi, P. Thavasu, A. Stewart, J. de Bono +4 more
2014Lung Cancer29 citations
Semantic Scholar
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group
A. Falcone, G. Masi, F. Loupakis, E. Vasile +6 more
200828 citations
Semantic Scholar
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
M. Puglisi, L. Molife, M. D. de Jonge, K. Khan +8 more
2021Future Oncology27 citations Open access
Semantic Scholar
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
I. Vergote, J. Sehouli, V. Salutari, P. Zola +14 more
2019Journal of Clinical Oncology27 citations
Semantic Scholar
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
M. O'Brien, J. Myerson, J. Coward, M. Puglisi +8 more
2012European Journal of Cancer27 citations
Semantic Scholar
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
L. Molife, S. Alam, David Olmos, M. Puglisi +7 more
2012Annals of Oncology26 citations Open access
Semantic Scholar
A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.
M. Puglisi, L. van Doorn, M. Blanco-Codesido, M. D. de Jonge +9 more
2011Journal of Clinical Oncology23 citations
Semantic Scholar
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
V. M. García, P. Thavasu, M. Codesido, L. Molife +8 more
2012British Journal of Cancer18 citations Open access
Semantic Scholar
ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
K. Fujiwara, I. Vergote, J. Sehouli, V. Salutari +15 more
2019Annals of Oncology8 citations Open access
Semantic Scholar
Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
L. Trani, J. Myerson, Stanley W. Ashley, K. Young +5 more
2010Lung Cancer8 citations
Semantic Scholar
A phase I clinical trial of a genetically modified and imageable oncolytic vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) imaging.
J. Pedersen, E. Karapanagiotou, A. Biondo, N. Tunariu +7 more
2011Journal of Clinical Oncology7 citations
Semantic Scholar
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions
M. Puglisi, A. Stewart, P. Thavasu, M. Frow +10 more
2016Oncology6 citations
Semantic Scholar
Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials
Montserrat Blanco Codesido, André Tesainer Brunetto, Sophia Frentzas, Victor Moreno Garcia +6 more
2011Oncology4 citations
Semantic Scholar
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.
S. Alam, R. Fehrmann, D. Olmos, K. Shah +6 more
20104 citations
Semantic Scholar
254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
D. Lorusso, Y. Xiang, N. Colombo, R. Coleman +16 more
20203 citations Open access
Semantic Scholar
ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer
R. Coleman, K. Fujiwara, J. Sehouli, V. Salutari +18 more
2020Gynecologic Oncology3 citations
Semantic Scholar
First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group
G. Masi, F. Loupakis, G. Baldi, L. Fornaro +11 more
20083 citations
Semantic Scholar
45 Preliminary results of a phase 1 study of intravenous administration of GL-ONC1 vaccinia virus including green-fluorescent protein real time imaging in patients with advanced cancer
J. Vitfell-Pedersen, E. Karapanagiotou, S. Alam, M. Puglisi +6 more
20102 citations
Semantic Scholar
261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer
D. Lorusso, Y. Xiang, N. Colombo, R. Coleman +16 more
2021Cervical cancer1 citations Open access
Semantic Scholar
An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
A. Minchom, K. Saksornchai, J. Bhosle, R. Gunapala +8 more
2014BMJ Open Respiratory Research1 citations Open access
Semantic Scholar
The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer.
J. Myerson, A. Faria, M. Puglisi, N. Starling +2 more
2010Lung Cancer1 citations
Semantic Scholar
Gender differences in comorbidities and outcomes of COVID-19 patients: findings from the "MASSI" study
A. Maugeri, M. Barchitta, G. Favara, Roberta San Lio +4 more
2023Population Medicine0 citations Open access
Semantic Scholar
EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer
D. Lorusso, Y. Xiang, N. Colombo, R. Coleman +16 more
2021E-Posters0 citations Open access
Semantic Scholar
164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
D. Lorusso, N. Colombo, R. E. Coleman, L. Randall +16 more
20200 citations Open access
Semantic Scholar
Characterization of the PI 3 K Pathway in Non-small Cell Lung Cancer Cells isolated from Pleural Effusions
M. Puglisi, A. Stewart, P. Thavasu, M. Frow +11 more
20160 citations
Semantic Scholar
Abstract 2441: Evaluation of combination of an EGFR and AKT inhibitor inEGFRmutant andEGFRwild type non-small cell lung cancer cells lines.
M. Puglisi, P. Thavasu, A. Stewart, J. Bhosle +3 more
20130 citations
Semantic Scholar
Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
B. Basu, J. Vitfell-Pedersen, V. M. García, M. Puglisi +8 more
2012Oncology0 citations Open access
Semantic Scholar
Abstract A92: A phase 1 safety and pharmacokinetic study of navitoclax in combination with docetaxel in patients with solid tumors.
F. Eskens, M. Gutierrez, D. Cosgrove, M. Puglisi +11 more
20110 citations
Semantic Scholar
Clinical outcome of patients with metastasic melanoma undergoing phase I clinical trials.
M. Blanco-Codesido, A. Brunetto, S. Frentzas, V. M. García +7 more
2011Journal of Clinical Oncology0 citations
Semantic Scholar
Therapeutic uses of topotecan for thoracic malignancies
S. Dolly, C. Carden, J. Myerson, M. Puglisi +1 more
20110 citations
Semantic Scholar
1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials
J. Vitfell-Pedersen, B. Basu, V. Moreno, A. Tjokrowidjaja +6 more
20110 citations
Semantic Scholar
449 Increased levels of serum creatine kinase caused by skin toxicity of molecularly targeted anticancer agents in phase 1 clinical trials
V. M. García, R. Molife, J. Pedersen, M. Puglisi +4 more
20100 citations
Semantic Scholar
An analysis of the risk of toxicity associated with participation in phase 1 oncology trials of novel molecularly targeted agents (mta) at the drug development unit, royal marsden hospital
S. Alam, R. Fehrmann, D. O. Hidalgo, K. Shah +6 more
20100 citations
Semantic Scholar
9062 The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients
A. Faria, J. Myerson, M. Puglisi, N. Starling +3 more
20090 citations
Semantic Scholar
9054 Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations
L. Trani, J. Myerson, K. Young, A. Sheri +4 more
20090 citations
Semantic Scholar
The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients
A. Faria, J. Myerson, M. Puglisi, N. Starling +4 more
20090 citations
Semantic Scholar
Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC)
G. Masi, F. Loupakis, E. Vasile, S. Cupini +16 more
20080 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

U. Banerji×14
Invite
U. Banerji — researcher profile on SciRah
J. de Bono×10
Invite
J. de Bono — researcher profile on SciRah
L. Molife×9
Invite
L. Molife — researcher profile on SciRah
S. Popat×9
Invite
S. Popat — researcher profile on SciRah

×9

Invite

M. O'Brien — researcher profile on SciRah

Invite

K. Shah — researcher profile on SciRah

Invite

D. Cibula — researcher profile on SciRah

Invite

J. Korach — researcher profile on SciRah

Invite

B. Basu — researcher profile on SciRah

Invite

J. Sehouli — researcher profile on SciRah

Invite

J. Myerson — researcher profile on SciRah

Invite

L. Trani — researcher profile on SciRah